Clinical Trials Logo

Clinical Trial Summary

The purpose of this clinical study is to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration (AMD).


Clinical Trial Description

This is a Phase 2, outcomes assessor-masked, multicentre, randomised study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with GA secondary to AMD. The trial includes a screening period of up to 8 weeks followed by a 96-week study period. Subjects will be randomised to one of two arms: GT005 or the untreated control group. Part 1 is conducted in a genetically selective sub-group of patients with GA secondary to AMD. Part 2 is conducted in a non-genetically selective sub-group of patients with GA secondary to AMD. This study is terminating early due to the interim analysis demonstrating lack of treatment efficacy. No additional subjects will be randomized or dosed. The trial is not ending early because of medical problems. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04437368
Study type Interventional
Source Gyroscope Therapeutics Limited
Contact
Status Active, not recruiting
Phase Phase 2
Start date July 14, 2020
Completion date March 29, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03046407 - Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells Phase 1/Phase 2
Active, not recruiting NCT04566445 - HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Phase 2
Recruiting NCT04339764 - Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT05536752 - QA102 Phase II Study in Subjects With Dry AMD Phase 2
Recruiting NCT06351605 - A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (EUROLIGHT) (EUROLIGHT)
Active, not recruiting NCT04065490 - Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III) N/A
Recruiting NCT06229665 - Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB) Phase 2/Phase 3
Completed NCT01002950 - Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy Phase 2
Active, not recruiting NCT03333954 - Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration N/A
Completed NCT05667688 - Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85 Phase 1
Completed NCT01379560 - A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration Phase 2
Completed NCT03144999 - Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59 Phase 1
Withdrawn NCT04511936 - Microcurrent Stimulation for Dry Age-related Macular Degeneration N/A
Withdrawn NCT04358471 - Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA) Phase 2
Terminated NCT04643886 - A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration Phase 2
Not yet recruiting NCT05418231 - Observation of the Natural Course of Age-related Macular Degeneration
Recruiting NCT00926861 - Posterior Macular Adhesion: A Potential Risk Factor for Non-exudative Age Related Macular Degeneration (AMD) to Develop Exudative AMD N/A
Active, not recruiting NCT03894020 - GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
Not yet recruiting NCT04875234 - Vision Improvement for Legally Blind Dry AMD Patients
Recruiting NCT02755428 - Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases Phase 1/Phase 2